EHCHealthcare · Medical Care FacilitiesThe 13 Wall Street analysts covering Encompass Health Corp. hold a median 12-month price target of $150 — +24.0% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 81 of 100 as at 22 Aug 2026 — inside the top quartile. Here, the model and the Street point the same way.
Consensus tells you what everyone already believes. The model scores Encompass Health Corp. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Quality (90): The business earns solid, repeatable profits on what it owns.
Momentum (52): The shares have been drifting down relative to others.
Size (14): Larger than most of the companies we track — more scrutinised, less often mispriced.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on EHC, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +24.0% from it.
Of the 20 most recent actions, 4 moved their price target up and 0 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 10 Aug 2026 | TD Cowen | Maintains | Buy | $125 → $140 |
| 7 Aug 2026 | Truist Securities | Maintains | Buy | $140 → $150 |
| 7 Aug 2026 | UBS | Maintains | Buy | $150 → $155 |
| 6 Aug 2026 | Barclays | Maintains | Overweight | $140 → $144 |
| 28 May 2026 | TD Cowen | Initiates | Buy | $125 |
| 28 May 2026 | TD Cowen | Initiates | Buy | — |
| 5 May 2026 | Barclays | Maintains | Overweight | — |
| 6 Feb 2026 | Barclays | Maintains | Overweight | — |
| 30 Oct 2025 | Barclays | Maintains | Overweight | — |
| 2 Oct 2025 | UBS | Maintains | Buy | — |
| 16 Sept 2025 | Keybanc | Maintains | Overweight | — |
| 10 Sept 2025 | B of A Securities | Maintains | Buy | — |
| 14 Aug 2025 | Truist Securities | Maintains | Buy | — |
| 6 Aug 2025 | UBS | Maintains | Buy | — |
| 5 June 2025 | Stephens & Co. | Reiterates | Overweight | — |
| 27 May 2025 | Keybanc | Maintains | Overweight | — |
| 28 Apr 2025 | RBC Capital | Maintains | Outperform | — |
| 28 Apr 2025 | Truist Securities | Reiterates | Buy | — |
| 28 Apr 2025 | UBS | Maintains | Buy | — |
| 25 Apr 2025 | Barclays | Maintains | Overweight | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. EHC appears on the weeks it earns a place.
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 39% of US stocks
Cheaper than 54% of US stocks
Cheaper than 24% of US stocks
Cheaper than 37% of US stocks
Higher than 51% of US stocks
Higher than 46% of US stocks
Higher than 99% of US stocks
Higher than 76% of US stocks
Higher than 70% of US stocks
Higher than 85% of US stocks
Higher than 92% of US stocks
Higher than 13% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Encompass Health Corp. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Zacks Investment Research highlights Encompass Health (EHC) as a top value stock for the long term, referencing its Zacks Style Scores as a method for identifying strong, market-beating stocks.
Why it matters — EHC watchers would care because the item positions the company favorably as a long-term value pick according to Zacks' stock-ranking methodology.
Zacks highlights Encompass Health's rising demand, higher patient acuity, and hospital expansion as growth drivers, while noting rising expenses and debt as key risks. The article presents these factors as supporting potential portfolio addition.
Why it matters — EHC watchers would care because the analysis weighs the company's expansion and demand drivers against its expense and debt pressures, offering a balanced view of its outlook.
Zacks Investment Research highlights Encompass Health (EHC) as a top growth stock for the long term, referencing its Zacks Style Scores as a tool for identifying strong, market-beating stocks.
Why it matters — EHC watchers may note the positive attention from a research firm positioning the company as a long-term growth stock.
An Encompass Health executive sold shares in an open-market transaction totaling roughly $1.1 million at a weighted average price of $125.95 per share, reducing his direct common stock holdings by 11%.
Why it matters — Insider selling can be watched by Encompass Health investors as a potential signal about management's view of the stock following a rate increase.
Encompass Health's CFO Coltharp sold 18,869 shares at an average of $125.38 per share on August 10, reducing his direct equity position by 27% and his total beneficial ownership by 7%, following a share-price jump after earnings.
Why it matters — A reduction in the CFO's personal stake is a notable insider-trading disclosure that Encompass Health watchers may track for signals about management's view of the stock.
The 13 Wall Street analysts covering Encompass Health Corp. have a median 12-month price target of $150, with estimates ranging from $140 to $155. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 13 analysts covering Encompass Health Corp., 13 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Encompass Health Corp. 81 out of 100 across roughly 4,600 US stocks as at 22 Aug 2026. None of this is personal advice — it does not consider your circumstances.
As at 22 Aug 2026, Encompass Health Corp. ranks 81 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Quality (90 of 100).
No one can know that. What the data says: the median 12-month target from 13 analysts implies +24.0% from the last close, and Ticker Nerd's factor model ranks Encompass Health Corp. 81 out of 100 as at 22 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Encompass Health Corp. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for EHC are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $140 to $155 over the next 12 months.
Encompass Health Corp. returned -0.9% over the 12 months to 24 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.
Encompass Health Corporation is a prominent American healthcare services company specializing in providing facility-based and home-based post-acute healthcare services. The organization operates through its network of inpatient rehabilitation hospitals, home health agencies, and hospice agencies across the United States.
The most recent item we track (Zacks Investment Research, 24 Aug 2026): "Why Encompass Health (EHC) is a Top Value Stock for the Long-Term". Zacks Investment Research highlights Encompass Health (EHC) as a top value stock for the long term, referencing its Zacks Style Scores as a method for identifying strong, market-beating stocks.
Encompass Health Corporation is a prominent American healthcare services company specializing in providing facility-based and home-based post-acute healthcare services. The organization operates through its network of inpatient rehabilitation hospitals, home health agencies, and hospice agencies across the United States. Encompass Health is dedicated to delivering high-quality, cost-effective care focused on enhancing patient outcomes following severe illnesses, surgeries, or injuries. The company plays a crucial role in the healthcare sector, particularly in rehabilitation and post-acute care, addressing the growing demand for comprehensive recovery solutions. Encompass Health Corporation is integral to the healthcare market, ensuring seamless patient transitions from hospital settings to recovery and long-term care, thereby contributing to the overall efficiency and modernization of the healthcare delivery system.
CEO Mr. Mark J. Tarr · 29,699 employees · United States · https://www.encompasshealth.com